A randomized, vehicle controlled, active comparator, parallel group study to evaluate safety, tolerability and preliminary efficacy of topical LFX453 formulations in patients with actinic keratosis

Trial Profile

A randomized, vehicle controlled, active comparator, parallel group study to evaluate safety, tolerability and preliminary efficacy of topical LFX453 formulations in patients with actinic keratosis

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2016

At a glance

  • Drugs LFX 453 (Primary) ; Imiquimod
  • Indications Actinic keratosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 01 Feb 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record
    • 23 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top